Veloxa Chewable Tablets for Dogs

Authorised

- Febantel
- Pyrantel
- Praziquantel

Product identification

Medicine name:
Veloxa Chewable Tablets for Dogs

Active substance:
Febantel

Pyrantel

Praziquantel

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Febantel
150.00 milligram(s) / 1.00 Tablet

Pyrantel

50.00 milligram(s) / 1.00 Tablet

Praziquantel
50.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP52AA51

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria

Package description:
PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 52 blister strips of 2 chewable tablets (104 chewable tablets)
PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 13 blister strips of 8 chewable tablets (104 chewable tablets)
PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 1 blister strip of 2 chewable tablets (2 chewable tablets)
PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 1 blister strip of 2 chewable tablets (2 chewable tablets)
PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 1 blister strips of 8 chewable tablets (8 chewable tablets)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Lavet Kft.

Marketing authorisation date:
21/09/2012

Manufacturing sites for batch release:
Lavet Kft.

Responsible authority:
Austrian Agency For Health And Food Safety

Authorisation number:
8-01117

Date of authorisation status change:
21/09/2012

Reference member state:
Hungary

Procedure number:
HU/V/0116/001

Concerned member states:
Austria Belgium Finland France Germany Greece Ireland Italy Luxembourg Netherlands Norway Portugal Spain Sweden

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 16/12/2021
Updated on: 13/03/2026
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.